This site is intended for healthcare professionals

Sign in

Round Up Email March 2022

This month's Round Up includes updates in a summary of the updated NICE Type 2 Diabetes guideline and the use of DOACs in cancer patients. Other highlights include an update on the NHS Galleri trial and a key facts page relating to burns associated with emollient use.

  • Question 1

    NHS Galleri Trial – This trial is designed to assess the performance and clinical utility of a multi-cancer early detection test (GalleriTM) for population screening in the United Kingdom (UK). The trial is summarised on GPnotebook.: NHS Galleri Trial

    1) With respect to the NHS Galleri trial, which statement is false

  • Question 2

    Burns associated with emollient use – if using a paraffin containing emollient then are only those containing more than 50% paraffin associated with significant fire risk? Is there a fire risk associated with paraffin-free emollients?: Burns (burn) with paraffin-containing and paraffin-free emollients

    2) With respect to burns associated with emollient use, which statement is false

  • Question 3

    Antibiotics and Sore Throat update – A Cochrane review has analysed antibiotic use in children and adults – does it conclude that antibiotic use reduces sore throat complications?: Antibiotics in sore throat

    3) With respect to antibiotics for sore throat, which statement is false

  • Question 4

    Use of DOACs in Cancer patients – how do DOACs compare to low molecular weight heparin in prevention of cancer-associated thrombosis (CAT)? Which agent is more likely to be associated with an increased risk of bleeding?: DOACs in cancer patients

    4) With respect to the use of DOACs in cancer, which statement is false

  • Question 5

    Updated NICE Type 2 Diabetes Guideline – this is summarised on GPnotebook.: NICE - algorithm for management of glycaemia (glucose) in type 2 diabetes

    5) With respect to the updated NICE Type 2 Diabetes guideline, which statement is false

  • Question 6

    Long term use of Proton Pump Inhibitors (PPIs) – is long-term use associated with hearing loss? Is there a risk of hearing loss/tinnitus if PPIs are used in patients with type 2 diabetes?: Proton pump inhibitors (PPIs) and hearing loss

    6) With respect to PPIs and hearing problems, which statement is false

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.